CD8A and non-small cell lung carcinoma: CD20+ TIBs have been shown to correlate with favorable prognosis in patients with NSCLC and ovarian cancer, possibly by acting as APCs to augment cytolytic T-cell responses.131,132 Notably, Cabrita et al. revealed that the formation of TLSs, as well as the cooccurrence of CD20+ B cells and CD8+ T cells in tumors, was associated with improved survival for patients with metastatic melanomas and could predict clinical outcomes of ICIs.133 In line with these observations, B cells have been implicated in immunotherapy responses.